Listing of the Claims:

1) (original) A dosage form comprising an alpha-2-adrenergic agonist and a trefoil factor family peptide.
2) (original) The dosage form of claim 1 wherein said dosage form is a solid.
3) (original) The dosage form of claim 1 wherein said dosage form is a liquid.
4) (original) The dosage form of claim 1 wherein said dosage form is a liquid suspension.
5) (original) The dosage form of claim 4 wherein the concentration of the alpha-2 adrenergic agonist is from 0.1% to 2%.
6) (original) The dosage form of claim 4 wherein the concentration of the alpha-2-adrenergic agonist is about 0.6%.
7) (canceled) The method of claim 4 wherein the concentration of the trefoil factor family peptide is from 0.1% to 1%.
8) (canceled) The method of claim 4 wherein the concentration of the trefoil factor family peptide is about 0.5%.
9) (original) The dosage form of claim 1 wherein said alpha-2-adrenergic agonist is selected from the group consisting of imidazole -2-thiones, quinoxaline derivatives, imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines, and mixtures thereof, or is a pharmaceutically acceptable salt thereof.
10) (original) The dosage form of claim 1 wherein said alpha-2-adrenergic agonist comprises brimonidine or a pharmaceutically acceptable salt thereof.
11) (original) The dosage form of claim 1 wherein said alpha-2-adrenergic agonist comprises an imidazole -2-thione or a pharmaceutically acceptable salt thereof.
12) (original) The dosage form of claim 1 comprising



or a pharmaceutically acceptable salt thereof.

13) (original) The dosage form of claim 1 comprising



or a pharmaceutically acceptable salt thereof.

14) (original) The dosage form of claim 1 which further comprises a mucoadhesive agent.

15) (original) The dosage form of claim 1 wherein the trefoil factor family peptide is TFF1.

16) (original) The dosage form of claim 1 wherein the trefoil factor family peptide is TFF2.

17) (original) The dosage form of claim 1 wherein the trefoil factor family peptide is TFF3.

18) (canceled) A method of treating glaucoma or reducing intraocular pressure comprising topically administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to an eye of a mammal suffering from glaucoma.

19) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in separate compositions.

20) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in a single composition.

21) (canceled) The method of claim 18 wherein the alpha-2-adrenergic agonist is administered at a concentration of from 0.005% to 0.5%.

22) (canceled) The method of claim 18 wherein the alpha-2-adrenergic agonist is administered at a concentration of from 0.02% to 0.2%.

23) (canceled) The method of claim 22 wherein the alpha-2-adrenergic agonist is administered at a concentration of about 0.03%.

24) (canceled) The method of claim 22 wherein the alpha-2-adrenergic agonist is administered at a concentration of about 0.1%.

25) (canceled) The method of claim 18 wherein the trefoil factor family peptide administered at a concentration from 0.001% to 1%.

26) (canceled) The method of claim 22 wherein the trefoil factor family peptide administered at a concentration from 0.01% to 0.5%.

27) (canceled) The method of claim 22 wherein the trefoil factor family peptide administered at a concentration from 0.1% to 0.2%.

28) (canceled) The method of claim 27 wherein the trefoil factor family peptide is administered at a concentration of about 0.15%.

29) (canceled) The method of claim 18 wherein a mucoadhesive agent is also administered to said patient.

30) (canceled) The method of claim 18 wherein said trefoil factor family peptide comprises TFF1 or TFF3.

31) (canceled) A method of treating a gastrointestinal disorder comprising administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to a mammal suffering from said disorder.

32) (canceled) The method of claim 31 wherein the gastrointestinal disorder comprises Crohn's disease, ulcerative colitis, gastritis, irritable bowel disease and chronic visceral pain.

33) (canceled) The method of claim 31 wherein the gastrointestinal disorder comprises ulcerative colitis.

34) (canceled) The method of claim 31 wherein the gastrointestinal disorder comprises irritable bowel disease.

35) (canceled) The method of claim 31 wherein the trefoil factor family peptide is TFF1.

36) (canceled) The method of claim 31 wherein the trefoil factor family peptide is TFF3.

37) (canceled) The method of claim 31 wherein the alpha-2 adrenergic agonist is administered at a concentration from 0.1% to 2%.

38) (canceled) The method of claim 37 wherein the alpha-2-adrenergic agonist is administered at a concentration of about 0.6%.

39) (canceled) The method of claim 38 wherein the trefoil factor family peptide is administered at a concentration from 0.1% to 1%

40) (canceled) The method of claim 39 wherein the trefoil factor family peptide is administered at a concentration of about 0.5%

41) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in separate dosage forms.

42) (canceled) The method of claim 18 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in a single dosage form.